FDA’s Big Mistake: Expect Flibanserin to Be Pulled From the Market in a Few Years

FDA’s Big Mistake: Expect Flibanserin to Be Pulled From the Market in a Few Years

August 19, 2015

View as PDF.

The U.S. Food and Drug Administration’s (FDA’s) decision to approve flibanserin as a treatment for women with hypoactive sexual desire presents serious dangers to women, with little benefit, and recklessly disregards the worrisome risk information in the agency’s briefing package to the advisory committees that met on June 4 to review the drug.